Skip to main content

Table 3 Meta-analysis of studies examining treatment uptake, treatment completion and SVR among people with Hepatitis C treated in a variety of community settings or specialist hospital care

From: A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments

Inclusion Criteria Treatment Uptake Treatment Completion SVR
  No. Of studies Heterogeneity
(I2)
Pooled estimate
(95% CI)
No. Of studies Heterogeneity
(I2)
Pooled estimate (95% CI) No. Of studies Heterogeneity
(I2)
Pooled estimate (95% CI)
Opioid Treatment Centres     2 77.7% 91.9 (82.2–100) 3 0.0% 82.3 (77.8–86.8)
Integrated Health System (ECHO) 1 Not applicable 75.6 (68.0–83.2) 1 Not applicable 96.8 (93.2–100) 2 84.6% 81.3 (66.9–95.5)
Telemedicine 1 Not applicable 22.3 (15.8–28.8)     1 Not applicable 51.4 (34.8–68.0)
Primary Care 1 Not applicable 67.4 (53.9–80.9) 1 Not applicable 100 (97.95–100) 5 94.9% 74.4 (60.3–88.5)
Pharmacies / Pharmacist Clinics 1 Not applicable 66.67 (58.3–75.1)     2 89.0% 79.0 (79.2–98.9)
Specialist Care 2 0.0% 34.5 (31.79–37.29)     5 96.8% 73.46 (60.9–85.9)
  1. Abbreviations: CI, Confidence interval; SVR, Sustained virologic response
  2. a. Random-effects method used if I2 ≥ 30%